National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
NCI Drug Dictionary
Page Options
Print This Page  Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Questions about cancer?

1-800-4-CANCER
Quit Smoking Today
Search for
Contains
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

bevacizumab  Patient Information
A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Synonyms:anti-VEGF humanized monoclonal antibody
anti-VEGF monoclonal antibody
anti-VEGF rhuMAb
recombinant humanized anti-VEGF monoclonal antibody
rhuMAb VEGF
US brand name:Avastin
Abbreviation:rhuMab-VEGF


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov